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Background: Neurofibromatosis 1 (NF1) is a complex and multifaceted neurocutaneous 
syndrome with many and varied comorbidities. The literature about the prevalence and degree 
of maternal stress and the impact of NF1 in the parent–child interaction is still scant. The aim 
of this study was to evaluate the prevalence of maternal stress in a large pediatric sample of 
individuals affected by NF1.
Methods: Thirty-seven children (19 boys, 18 girls) of mean age 7.86±2.94 (range 5–11) years 
affected by typical NF1 and a control group comprising 405 typically developing children 
(207 boys, 198 girls; mean age 8.54±2.47 years) were included in this study. To assess paren-
tal stress, the mothers of all individuals (NF1 and comparisons) filled out the Parenting Stress 
Index-Short Form test.
Results: The two study groups were comparable for age (P=0.116), gender (P=0.886), and body 
mass index adjusted for age (P=0.305). Mothers of children affected by NF1 reported higher 
mean Parenting Stress Index-Short Form scores on the Parental Distress domain (P,0.001), 
Difficult Child domain (P,0.001), and Total Stress domain than the mothers of typically 
developing children (controls) (P,0.001). No significant differences between the two groups 
were found for the Parent-Child Dysfunctional Interaction domain (P=0.566) or Defensive 
Responding domain scores (P=0.160).
Conclusion: NF1 is considered a multisystemic and complex disease, with many still unrec-
ognized features in pediatric patients and in their families. In this light, our findings about the 
higher levels of maternal stress highlight the importance of considering the environmental 
aspects of NF1 management in developmental age.
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Introduction
Neurocutaneous syndromes are a group of genetic pathologies linked to the common 
alteration in development of neural crest.1 In general, the primary neurocutaneous 
syndromes are all very different diseases with different genetic mutations, but the 
unifying factor amongst them is that all are neurocristopathies and can be explained 
as such, including the tumor-suppressor function of several of these genes, especially 
those of neurofibromatosis 1 and 2 and tuberous sclerosis complex.1
NF1 (OMIM #162200)2 was first described in 1882 by von Recklinghausen, and 
is among the most common autosomal dominant disorders, with a prevalence of one 
in 4,000 individuals worldwide,3,4 caused by the NF1 gene mutation coded by chro-
mosome 17q11.2, with the subsequent alteration in Ras-mediated cell proliferation 
modulation.5,6





Nervous system involvement in NF1 can cause learning 
disabilities; plexiform neurofibromas; megalencephaly; cere-
bral tumors; headache; acqueductal stenosis; cerebrovascular 
disease; meningoceles; neurofibromatous neuropathy; and 
cerebral high-signal lesions, visible on T2-weighted magnetic 
resonance images.7–10 The varied clinical NF1 manifestations 
could significantly impact family relationships, as described 
by Ablon in 2000, who, in 16 families studied, reported shock, 
upset, and subsequent depression as responses to NF1 diag-
nosis,11 pinpointing the relevance of the parents’ emotional 
reactions in NF1 management. On the other hand, behavioral 
aspects and parental stress of children and adolescents with 
several disabling genetic and/or chronic conditions were 
previously described,12,13 and the role of parental stress in 
the management of childhood chronic illnesses14–17 was 
demonstrated.
To date, reports concerning the impact of neurocutaneous 
syndrome in parental stress management and parent–child 
interactions are scant. Therefore, the aim of the present study 
was to assess the maternal stress levels in a population of 
school-aged children affected by NF1.
Materials and methods
Study population
The study population comprised 37 children (19 boys, 
18 girls) of mean age 7.86±2.94 (range 5–11) years affected 
by typical NF1 and referred consecutively to the Clinic of 
Child and Adolescent Neuropsychiatry at the Second Univer-
sity of Naples, to the Department of Psychiatry at the “Magna 
Graecia” of Catanzaro University and to the Child Neurop-
sychiatry of the Department of Psychology at the University 
of Palermo from January 2012 to September 2013.
The diagnosis of NF1 was made accord ing to the clini-
cal criteria, established by the National Institutes of Health 
consensus in 198718,19 and the reassessed version of 1997.20
The control group was composed of 405 typically develop-
ing controls (207 boys, 198 girls; mean age 8.54±2.47 years) 
recruited from schools in the Campania and Umbria regions 
of Italy. Subjects of both groups were recruited from the same 
urban area, and were all of Caucasian origin and of middle 
socioeconomic status (within class 2 or class 3, corresponding 
to €28,000–€55,000/year and €55,000–€75,000/year, respec-
tively, according to current Italian economic parameters), as 
previously reported.21
For both populations, the exclusion criteria were 
the following: allergies; endocrinological problems (eg, 
diabetes); preterm birth;22,23 epilepsy; psychiatric symp-
toms (such as attention deficit hyperactivity disorder, 
depression, and behavioral problems); mental retardation 
(IQ#70); previous rehabilitative treatment;24 borderline 
intellectual functioning (IQ ranging from 71–84);25,26 
overweight (body mass index [BMI] $85th percentile) or 
obesity (BMI $95th percentile);27,28 sleep disorders;29–34 
primary nocturnal enuresis;35–37 and psychoactive drug 
administration.38,39
All parents gave their written informed consent. The 
Clinical Departmental University Ethics Committee at the 
Second University of Naples approved the study protocol, 
and the study was conducted according to the criteria of the 
Declaration of Helsinki as modified in 2000.40
parenting Stress Index-Short  
Form (pSI-SF)
To assess the perceived stress in mothers of children with NF1, 
the Italian version of the PSI-SF was used.41 The PSI-SF is a 
standardized tool that yields scores for parental stress across 
four areas via Parental Distress and Parent-Child  Dysfunctional 
Interaction domains and Difficult Child and Total Stress 
 subscales. It has 36 items and provides both raw and  percentile 
scores. Each item is graded on a five-point  Likert scale, 
from 1 (strongly disagree) to 5 (strongly agree).
The Parental Distress domain measures the dis tress that 
parents feel about their parenting role in light of other per-
sonal stresses, and has a cut-off score of 36; the Parent-Child 
Dysfunctional Interaction domain focuses on the perception 
of the child as not responsive to parental expectations, and 
has a cut-off score of 27; and the Difficult Child subscale 
represents behaviors that children often engage in that may 
make parenting easier or more difficult, and has a cut-off 
score of 36.
The PSI-SF also produces a Defensive Responding sub-
scale score, which indicates likely response bias. The subscale 
scores range from 12 to 60, and the Total Stress subscale 
scores ranges from 36 to 180, with higher scores indicating 
greater levels of parental stress. Thus, responses higher than 
the 85th percentile (one standard deviation above the mean) 
are interpreted as “clinically significant” for high levels of 
family stress.41
The PSI-SF has been used widely, and psychometric 
evidence supports its reliability and validity.37,38 The PSI-SF 
shows high internal consistency (Cronbach’s alpha 0.92), 
and its validity has been established in parents of children 
with chronic medi cal conditions, including diabetes and 
asthma.42–44 In this study, the PSI-SF was administered only 
to the mother, being the parent assumed to usually spend 
more time with the children.




Parental stress and pediatric neurofibromatosis 1
Statistical analysis
The t-test and chi-square test were applied as  appropriate 
to compare the characteristics (age, gender and BMI 
adjusted for age) and the PSI-SF results between the two 
 populations. P-values ,0.05 were considered to be statisti-
cally significant.
All data were coded and analyzed using the commer-
cially available STATISTICA package for Windows (v 6.0; 
StatSoft Inc, Tulsa, OK, USA).
Results
The two study groups were comparable for age (P=0.116), 
gender (P=0.886), and BMI adjusted for age (P=0.305), as 
shown in Table 1.
Mothers of children affected by NF1 reported higher 
mean PSI-SF scores on the Parental Distress domain 
(P,0.001), Difficult Child subscale (P,0.001), and Total 
Stress subscale score (P<0.001) than the mothers of typically 
developing children, as shown in Table 2.
No relevant differences between the two groups were 
found for the Parent-Child Dysfunctional Interaction 
domain (P=0.566) or Defensive Responding domain scores 
(P=0.160) (Table 2).
Discussion
The main finding of the present study was that there were 
higher stress levels in mothers of children affected by NF1 
compared with mothers of healthy children (33.19±11.02 vs 
26.94±5.44; P,0.001) and in the Difficult Child subscale 
(26.14±5.03 vs 22.96±3.19; P,0.001), even though their 
scores did not fall within the pathological ranges.
To interpret and understand these findings correctly, we 
could speculate that, while NF1 is an autosomal dominant condi-
tion, one half of all cases are thought to represent de novo muta-
tions, with clinical characteristics that are often frightening for 
parents and unpredictable symptom progression.11 In this light, 
our results about the higher quote of the parental stress total level 
and in the Difficult Child subscale may be interpreted.
NF1 is an extremely variable condition, the morbidity 
and mortality of which is largely dictated by complications 
that are numerous and can involve any body system;3,4,45 
the stress of mothers of NF1 children may be interpreted as 
linked to the varied comorbidities of the illness. Moreover, the 
prognosis of NF1 remains unpredictable, with the possibility 
of complications affecting various organs, such as central 
nervous system cancer that can also involve the PTEN gene 
functions, even if not exclusively.46–48
NF1 affects all aspects of a child’s life, because it is 
associated with cognitive impairment, learning disabilities, 
and neuropsychological deficits;49–55 sleep alterations; and 
hyperactivity.56 NF1 also contributes to parental distress and 
affects family functioning,57,58 both of which could be influ-
enced by parents’ consideration of the child as “different” 
from other children, even if in an undefined way.
We could speculate that the high stress levels identified 
in mothers of NF1 children could be due not only to the 
specific characteristic of the NF1, that can be physically 
disfiguring, but also to the frequent clinical hospital controls, 
as with other chronic illness (eg, diabetes, asthma, primary 
ciliary dyskinesia, cystic fibrosis, migraine, and celiac 
disease).17,59–63 Specifically, parents of children affected by 
other genetic chronic illnesses seem to experience higher 
stress levels and greater burdens than parents of healthy 
children, yet parenting behavior and family functioning have 
been found to be quite similar to those of healthy control 
groups.61,62
In general, we can assume that, when a child is diagnosed 
with a chronic, life-threatening illness, there is a significant 
impact on the other family members, and the  stress of par-
enting tends to reflect the level of stress/difficulty present in 
the parent–child relationship, including stress attributable to 
parental distress, difficult child characteristics, and dysfunc-
tional parent–child interactions. Notably, research conducted 
by Hung et al in 200464 suggested that different illnesses may 
Table 1 Age, gender and z-score Body Mass Index (z-BMI) 
differences between children affected by neurofibromatosis 1 
(NF1) and typically developing children (controls)
NF1 (N=37) Controls (N=405) P
Age, years 7.86±2.94 8.54±2.47 0.116
Gender (M/F) 19/18 207/198 0.886
z-BMI 0.56±0.19 0.52±0.23 0.305
Notes: Data are expressed as mean ± standard deviation or number. The t-test and 
chi-square test, where appropriate, were applied. P-values ,0.05 were considered 
statistically significant.
Table 2 Differences in pSI-SF42 domain scores between mothers 
of children with NF1 and mothers of normal healthy controls
PSI-SF domains NF1 (N=37) Controls (N=405) P
pD 33.19±11.02 26.94±5.44 ,0.001
pCDI 21.86±4.91 22.18±3.05 0.566
DC 26.14±5.03 22.96±3.19 ,0.001
DeF 12.93±5.04 13.96±4.19 0.160
TS 84.53±6.09 65.27±4.39 ,0.001
Notes: Data are expressed as mean ± standard deviation. The t-test was applied. 
P-values,0.05 were considered statistically significant.
Abbreviations: pSI-SF, parenting Stress Index-Short Form; pD, parental Distress; 
PCDI, Parent-Child Dysfunctional Interaction; DC, Difficult Child; DEF, Defensive 
responding; TS, Total Stress.





result in different levels of stress of parenting, ie parenting of 
children affected by chronic illness can be a stressful condi-
tion in itself, becoming a vicious circle.
Conflict over child care responsibilities and decision-
making are the most commonly reported stresses experienced 
by parents caring for children with a chronic illness.65–67 In 
2010, Hullmann et al reported that parents of children with 
asthma who experience strained interactions with their child 
or are highly critical of their children are less likely to engage 
in effective disease management strategies and have children 
with more severe asthma.68 Therefore, these studies suggest 
that children’s health outcomes are related to how well their 
parents function and adhere to the prescribed regimen. This 
seems to be particularly important for parents of children 
with cystic fibrosis, diabetes, and asthma, as most of the 
daily treatments are performed by parents.68
The toll that NF1 takes on families may be identified 
also in the oncologic potential of NF1 leads per se, linked 
to the role of neurofibromin protein as a tumor-suppressor 
gene and inhibitor of the Ras/mitogen-activated protein 
kinase pathway that is an important regulator of cellular 
growth and differentiation, aiding the dephosphorylation 
of ras guanosine triphosphate.69 In this perspective, the 
high maternal stress levels, expressed as difficult child 
perception (26.14±5.03 of NF1 mothers versus 22.96±3.19 
of mothers of comparisons, P<0.001), could also represent 
as the effect of the fear for life-threatening complications, 
such as cancer.
On the other hand, we have to clarify that the higher 
stress levels in mothers of NF1 children respect of mother 
of comparisons were not in the pathological range. In this 
light, these findings suggest that psychological support for 
parents with children affected by NF1 could help to prevent 
the developing of clinically evident difficulties in parent–
child interactions that could further worsen the quality of 
life of children affected by NF1.
We should take into account some limitations of this 
study: 1) our data were derived from a small group affected 
by NF1 from a specific region of southern Italy; and 2) the 
assessment of parental stress levels was undertaken only in 
the mothers.
Notwithstanding these limitations, this could be con-
sidered a first report about parental stress evaluation in 
NF1, which is a multisystemic and complex disease with 
many still unrecognized features in pediatric patients and 
in their families. Our findings about the higher levels of 
maternal stress highlight the importance of considering 
the environmental aspects of NF1 management in 
developmental age, and suggest that specific psychological 
support could be of benefit to pediatric NF1 patients and 
their families.
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